Insulet (PODD) Revenue — Quarter Ended Dec 31, 2023
Revenue increased in the quarter, driven by continued demand for the company's insulin delivery systems. Growth was observed both sequentially and compared to the same period last year.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Revenue increased in the quarter, driven by continued demand for the company's insulin delivery systems. Growth was observed both sequentially and compared to the same period last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$509.8M
Revenue reported for this quarter.
Quarter-over-quarter
+17.8%
Change from the immediately preceding quarter.
Year-over-year
+37.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$1.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $358.1M | +45.0% |
| Jun 30, 2023 | $396.5M | +32.4% |
| Sep 30, 2023 | $432.7M | +27.0% |
| Dec 31, 2023 | $509.8M | +37.9% |
Revenue performance
The company reported higher revenue for the quarter, continuing its upward trajectory.
Quarterly comparison
Revenue grew compared to the prior quarter, and also increased substantially versus the same quarter one year earlier.
What to watch
Monitor the company's ability to sustain sequential revenue growth in future quarters.